** Shares of drugmaker Sage Therapeutics SAGE.O rise 36.4% to $7.57 premarket
** Drugmaker Biogen BIIB.O will buy all outstanding shares of Sage that it does not already own for $7.22 apiece, a filing showed on Friday
** The offer price, representing a 30% premium to stock's close on Friday, values Sage's equity at $441.7 mln, according to Reuters calculations
** Brokerage William Blair says the offer is prudent to maximize potential for Sage and Biogen's depression drug, Zurzuvae, without materially impacting Biogen's M&A deal capacity
** Up to last close, stock down 78.1% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.